• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adherence matters: catastrophic NMOSD relapse after missed eculizumab infusions.

作者信息

Sredanović Mašan, Tešija Katarina, Adamec Ivan, Habek Mario

机构信息

Department of Neurology, Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Kišpatićeva 12, HR-10000, Zagreb, Croatia.

School of Medicine, University of Zagreb, Zagreb, Croatia.

出版信息

J Neurol. 2025 Jul 29;272(8):543. doi: 10.1007/s00415-025-13263-1.

DOI:10.1007/s00415-025-13263-1
PMID:40728563
Abstract
摘要

相似文献

1
Adherence matters: catastrophic NMOSD relapse after missed eculizumab infusions.坚持治疗很重要：错过依库珠单抗输注后，视神经脊髓炎谱系障碍出现灾难性复发。
J Neurol. 2025 Jul 29;272(8):543. doi: 10.1007/s00415-025-13263-1.
2
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.抗 eculizumab 治疗后血清阳性视神经脊髓炎谱系疾病患者严重疾病再激活。
Mult Scler Relat Disord. 2023 Nov;79:104949. doi: 10.1016/j.msard.2023.104949. Epub 2023 Aug 25.
3
Eculizumab for a catastrophic relapse in NMOSD: case report.依库珠单抗治疗 NMOSD 灾难性复发 1 例报告
Neurol Sci. 2024 Jan;45(1):249-251. doi: 10.1007/s10072-023-06971-x. Epub 2023 Jul 27.
4
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.依库珠单抗治疗水通道蛋白4抗体阳性视神经脊髓炎谱系障碍患者的长期安全性和有效性：日本上市后监测的2年中期分析
Ther Adv Neurol Disord. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177. eCollection 2023.
5
Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies.依库珠单抗或ravulizumab治疗视神经脊髓炎谱系障碍患者的效果：三项研究的通俗易懂总结
J Comp Eff Res. 2025 Apr;14(4):e240177. doi: 10.57264/cer-2024-0177. Epub 2025 Feb 12.
6
Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report.依库珠单抗治疗视神经脊髓炎谱系障碍急性复发：病例报告。
Front Neurol. 2022 Aug 8;13:951423. doi: 10.3389/fneur.2022.951423. eCollection 2022.
7
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.依库珠单抗治疗水通道蛋白4阳性视神经脊髓炎谱系障碍的益处：3期随机对照PREVENT试验的亚组分析
Mult Scler Relat Disord. 2021 Jan;47:102641. doi: 10.1016/j.msard.2020.102641. Epub 2020 Nov 26.
8
The Efficacy of Eculizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study.依库珠单抗在视神经脊髓炎谱系障碍急性期的疗效：一项病例系列研究。
Cureus. 2024 Nov 7;16(11):e73205. doi: 10.7759/cureus.73205. eCollection 2024 Nov.
9
Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系障碍患者从依库珠单抗转换为萨特利珠单抗后出现严重复发。
Neurology. 2025 Mar 11;104(5):e213399. doi: 10.1212/WNL.0000000000213399. Epub 2025 Feb 6.
10
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.瑞武利单抗与其他治疗视神经脊髓炎谱系障碍干预措施的网状Meta分析
Neurol Ther. 2024 Jun;13(3):535-549. doi: 10.1007/s40120-024-00597-7. Epub 2024 May 9.

本文引用的文献

1
Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系障碍患者从依库珠单抗转换为萨特利珠单抗后出现严重复发。
Neurology. 2025 Mar 11;104(5):e213399. doi: 10.1212/WNL.0000000000213399. Epub 2025 Feb 6.
2
Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies.新一代生物疗法背景下视神经脊髓炎谱系障碍的疾病修饰治疗
Rev Neurol (Paris). 2025 Jan-Feb;181(1-2):42-51. doi: 10.1016/j.neurol.2024.01.008. Epub 2024 Mar 28.
3
The psychological burden of NMOSD - a mixed method study of patients and caregivers.
视神经脊髓炎谱系疾病患者及其照护者的心理负担：混合方法研究。
PLoS One. 2024 Mar 29;19(3):e0300777. doi: 10.1371/journal.pone.0300777. eCollection 2024.
4
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.抗 eculizumab 治疗后血清阳性视神经脊髓炎谱系疾病患者严重疾病再激活。
Mult Scler Relat Disord. 2023 Nov;79:104949. doi: 10.1016/j.msard.2023.104949. Epub 2023 Aug 25.
5
Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.AQP4 阳性视神经脊髓炎谱系疾病患者应用拉维珠单抗治疗。
Ann Neurol. 2023 Jun;93(6):1053-1068. doi: 10.1002/ana.26626. Epub 2023 Apr 5.
6
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder.依库珠单抗在视神经脊髓炎谱系障碍患者中的药代动力学和药效学
Front Neurol. 2021 Nov 3;12:696387. doi: 10.3389/fneur.2021.696387. eCollection 2021.
7
Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum Disorder With Long-Term Remission.血清学阳性的视神经脊髓炎谱系障碍长期缓解后停用免疫抑制剂后的复发
J Clin Neurol. 2021 Oct;17(4):599-601. doi: 10.3988/jcn.2021.17.4.599.
8
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.视神经脊髓炎谱系疾病患者抗水通道蛋白 4 抗体治疗的停药。
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2). doi: 10.1212/NXI.0000000000000947. Print 2021 Mar.
9
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.抗水通道蛋白 4 抗体阳性视神经脊髓炎谱系疾病的治疗
N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
10
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.依库珠单抗治疗水通道蛋白 4 免疫球蛋白 G 阳性复发性视神经脊髓炎谱系疾病：一项开放标签的初步研究。
Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26.